Selective modulation of the prostaglandin F2α pathway markedly impacts on endometriosis progression in a xenograft mouse model
Lab / animal
OA: bronze
CC0
⤵ 11 in-corpus citations
AI-generated summary
Selective antagonism of the prostaglandin F2α receptor significantly reduced endometriosis lesion growth, angiogenesis, and proliferation while increasing apoptosis in a mouse model.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
STUDY HYPOTHESIS: Selective activation or blockade of the prostaglandin (PG) F2α receptor (FP receptor) affects ectopic endometrial tissue growth and endometriosis development.
STUDY FINDING: FP receptor antagonists might represent a promising approach for the treatment of peritoneal endometriosis.
WHAT IS KNOW ALREADY: Eutopic and ectopic endometrium from women with endometriosis exhibit higher expression of key enzymes involved in the PGF2α biosynthetic pathway. It has also been shown that the PGF2α-FP receptor interaction induces angiogenesis in human endometrial adenocarcinoma.
STUDY DESIGN, SAMPLES/MATERIALS, METHODS: For this study, a mouse model of endometriosis was developed by inoculating human endometrial biopsies into the peritoneal cavity of nude mouse (n = 15). Mice were treated with AL8810 (FP receptor antagonist), Fluprostenol (FP receptor agonist) or PBS. Endometriosis-like lesions were collected and analysed for set of markers for angiogenesis, tissue remodelling, apoptosis, cell proliferation and capillary formation using qPCR and immunohistochemistry.
MAIN RESULTS AND THE ROLE OF CHANCE: We found that selective inhibition of the FP receptor with a specific antagonist, AL8810, led to a significant decline in the number (P < 0.01) and size of endometriosis-like lesions (P < 0.001), down-regulated the expression of key mediators of tissue remodelling (MMP9, P < 0.05) and angiogenesis (VEGF, P < 0.01) and up-regulated the pro-apoptotic factor (Bax, P < 0.01) as compared with controls. Immunohistochemical analyses further showed a marked decrease in cell proliferation and capillary formation in endometrial implants from AL8810-treated mice, as determined by proliferating cell nuclear antigen (PCNA) and von Willebrand factor (vWF) immunostaining, respectively. Moreover, Fluprostenol, a selective FP receptor agonist, showed the opposite effects.
LIMITATIONS, REASONS FOR CAUTION: We carried out this study in nude mice, which have low levels of endogenous estrogens which may affect the lesion growth. Caution is required when interpreting these results to women.
WIDER IMPLICATIONS OF THE FINDINGS: This study extends the role of PG signalling in endometriosis pathogenesis and points towards the possible relevance of selective FP receptor antagonism as a targeted treatment for endometriosis.
LARGE SCALE DATA: Not Applicable.
STUDY FUNDING AND COMPETING INTERESTS: This work was supported by grant MOP-123259 to the late Dr Ali Akoum from the Canadian Institutes for Health Research. The authors have no conflict of interest.
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood (2-hop)
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]
References (51)
- Clinical practice. Endometriosis via openalex
- Cyclooxygenase-2 expression in deep endometriosis and matched eutopic endometrium via openalex
- Distribution of cyclooxygenase-2 in eutopic and ectopic endometrium in endometriosis and adenomyosis via openalex
- Endometriosis via openalex
- Endometriosis and infertility: a review of the pathogenesis and treatment of endometriosis-associated infertility via openalex
- Endometriosis: pathogenesis and treatment via openalex
- Expression of aromatase and estrogen sulfotransferase in eutopic and ectopic endometrium: evidence for unbalanced estradiol production in endometriosis via openalex
- Genetic variants underlying risk of endometriosis: insights from meta-analysis of eight genome-wide association and replication datasets via openalex
- HOX gene expression is altered in the endometrium of women with endometriosis via openalex
- Identification of multiple and distinct defects in prostaglandin biosynthetic pathways in eutopic and ectopic endometrium of women with endometriosis via openalex
- Increased expression of matrix metalloproteinase-9 in the eutopic endometrial tissue of women with endometriosis via openalex
- Matrix metalloproteinase-2, membranous type 1 matrix metalloproteinase, and tissue inhibitor of metalloproteinase-2 expression in ectopic and eutopic endometrium via openalex
- Metastatic or Embolic Endometriosis, due to the Menstrual Dissemination of Endometrial Tissue into the Venous Circulation via openalex
- Peritoneal fluid prostaglandins and prostanoids in women with endometriosis, chronic pelvic inflammatory disease, and pelvic pain via openalex
- PPARγ activation inhibits growth and survival of human endometriotic cells by suppressing estrogen biosynthesis and PGE2 signaling via openalex
- Prostaglandin receptor signalling and function in human endometrial pathology via openalex
- Role of endometriosis in cancer and tumor development via openalex
- W2129103567 via openalex
- W2129935236 via openalex
- W2140246703 via openalex
- W2142046360 via openalex
- W2144284013 via openalex
- W2153278559 via openalex
- W2155602568 via openalex
- W2158087731 via openalex
- W2162317646 via openalex
- W2269513378 via openalex
- W2282854645 via openalex
- W2994377017 via openalex
- W4230437325 via openalex
- W4237504024 via openalex
- W4249215891 via openalex
- W4406056646 via openalex
- W6604186803 via openalex
- W6632794066 via openalex
- W1533085687 via openalex
- W1543698132 via openalex
- W1966313125 via openalex
- W1970690912 via openalex
- W2007145953 via openalex
- W2011046820 via openalex
- W2060692647 via openalex
- W2066549596 via openalex
- W2074126807 via openalex
- W2078950332 via openalex
- W2085890671 via openalex
- W2088426128 via openalex
- W2090653254 via openalex
- W2093246348 via openalex
- W2104244553 via openalex
- W2126279698 via openalex
Cited by (12)
- Endometriosis-associated Pain: Mechanism, Neuroimmune Signature, and Translational Precision Strategies 2026
- WERF Endometriosis Phenome and Biobanking Harmonisation Project for Experimental Models in Endometriosis Research (EPHect-EM-Heterologous): heterologous rodent models 2025
- Endometriosis and Endometriosis-Associated Tumors 2025
- Endometriosis and Endometriosis-Associated Tumors 2024
- Endometriosis: recent advances that could accelerate diagnosis and improve care 2024
- Involvement of bradykinin and bradykinin B1 receptor in patients with endometriosis 2021
- Endometriosis and Endometriosis-Associated Tumors 2019
- Aldo-keto reductase 1C3-Assessment as a new target for the treatment of endometriosis 2019
- PTGFR activation promotes the expression of PTGS-2 and growth factors via activation of the PKC signaling pathway in bovine endometrial epithelial cells 2018
- Perineural invasion in endometriotic lesions contributes to endometriosis-associated pain 2018
- Animal models of endometriosis: Replicating the aetiology and symptoms of the human disorder 2018
- Basic mechanisms of vascularization in endometriosis and their clinical implications 2018
SciLite annotations
organisms 7
transgenic mice
human
transgenic mice
human
transgenic mice
mus sp.
mus sp.
chemicals 3
fluprostenol
fluprostenol
estrone
Source provenance
- europepmc
- last seen: 2026-10-14T06:08:39.101224+00:00
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- pubmed
- last seen: 2026-10-08T21:16:31.290043+00:00
- scilite
- last seen: 2026-05-18T04:25:29.313245+00:00
License: CC0
· commercial use OK